Prescient Therapeutics (ASX:PTX) secured authorization from the European Clinical Trials Information System to begin its clinical trial for cancer drug candidate PTX-100 in patients with relapsed/refractory cutaneous T-cell lymphoma in Italy, according to a Monday filing with the Australian bourse.
The approval enables the activation of trial sites and patient recruitment for the phase 2A study in Europe, the filing said.
Shares rose 9% in afternoon trade on Monday and earlier reached their highest since April 2023.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments